期刊文献+

糖尿病患者药物治疗的个体化考虑 被引量:4

Drug treatment for diabetic patients needs considering individual characteristics
下载PDF
导出
摘要 糖尿病是以血糖升高为主要表现的常见非传染性流行病,每个患者都有其自身的特点,因此指南基础上的个体化治疗是糖尿病长期控制达标的基石。作者介绍糖尿病患者的空腹、餐后高血糖或组合特点和血糖控制目标,以表格的形式概括降糖药物的基本特性和不同药物对空腹或餐后血糖的作用优劣。根据血糖升高特点和药物作用特性,更加合理地选用药物,尽可能在有效降糖的同时,使其不良反应最小化,实现个体化治疗。 Diabetes mellitus is a common non-infectious disease with hyperglycemic charac-teristics, but every patient has his feature .Individualized therapy based on guideline is a successful cornerstone for achiving treatment target in diabetes mellitus .In the review, the fasting, postprandial or combined hyperglycemia features are introduced firstly , then the important features of different drugs are mentioned by means of figure or table .Finally, based on the predicted HbA 1c target and patient ’s concrete manifestations , the drugs which matches the patient best are chosen for better effects and lesser adverse reaction .
作者 姚合斌
出处 《转化医学杂志》 2015年第6期351-353,356,共4页 Translational Medicine Journal
基金 解放军总后勤保健专项课题(CWS14BJ38)
关键词 糖尿病 糖化血红蛋白A1C 不良反应 个体化 Diabetes mellitus Glycosylated hemoglobin A1c(Hb A1c) Adverse reaction Personalised
  • 相关文献

参考文献10

  • 1Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults. The Journal of The American Medical Association . 2013
  • 2Dluhy Robert G,McMahon Graham T.Intensive glycemic control in the ACCORD and ADVANCE trials. The New England Quarterly . 2008
  • 3Salvo MC,Brooks AD,Thacker SM.Patient considerations in the management of type 2 diabetes-critical appraisal ofdapagliflozin. Patient Prefer Adherence . 2014
  • 4中国成人2型糖尿病HbA_(1c)控制目标的专家共识[J].中国医学前沿杂志(电子版),2011,3(4):73-77. 被引量:29
  • 5S. E. Inzucchi,R. M. Bergenstal,J. B. Buse,M. Diamant,E. Ferrannini,M. Nauck,A. L. Peters,A. Tsapas,R. Wender,D. R. Matthews.??Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)(J)Diabetologia . 2012 (6)
  • 6Jeffrey Unger.??Uncovering undetected hypoglycemic events(J)Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy . 2012 (defa)
  • 7A. J.Scheen.??Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors(J)Diabetes, Obesity and Metabolism . 2010 (8)
  • 8Goldstein B,Mueller-Wieland D.Type 2 diabetes:principles and practice. . 2007
  • 9Dardano A,Penno G,Del Prato S,et al.Optimal therapy of type 2 diabetes:a controversial challenge. Aging (Albany NY) . 2014
  • 10Anderson M,Powell J,Campbell KM,et al.Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia. Diabetes Metab Syndr Obes . 2014

二级参考文献31

  • 1中华医学会糖尿病学分会.中国2型糖尿病防治指南.中华内分泌代谢杂志,2008,24(2).
  • 2Nathan DM;Cleary PA;Backlund JY.Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes[J]New England Journal of Medicine,2005(25):2643-2653.
  • 3Rodbard HW;Jellinger PS;Davidson JA.Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus:an algorithm for glycemic control[J]Endocrine Practice,2009(06):540-559.
  • 4UK Prospective Diabetes Study (UKPDS) Group.Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]The Lancet,1998(9131):837-853.
  • 5American Diabetes Association.Standards of medical care in diabetes-2010[J]Diabetes Care,2010(Suppl 1):11-61.
  • 6The ACCORD Study Group.Effects of intensive blood-pressure control in type 2 diabetes mellitus[J]New England Journal of Medicine,2010(17):1575-1585.
  • 7Steffes M;Molitch M;Chavers B.Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy:the Epidemiology of Diabetes Interventions and Complications (EDIC) study[J]Journal of the American Medical Association,2003(16):2159-2167.
  • 8Shichiri M;Kishikawa H;Ohkubo Y.Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients[J]Diabetes Care,2000(Suppl 2):21-29.
  • 9Chalmers J;Cooper ME.UKPDS and the legacy effect[J]the New England Journal of Medicine,2008(15):1618-1620.
  • 10Reaven PD;Moritz TE;Schwenke DC.Intensive glucoselowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis[J]Diabetes,2009(11):2642-2648.

共引文献37

同被引文献30

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部